In Australia, Collagen Solutions PLC, which is registered in London and has global headquarters in Minnesota, received additional patent protection. The patent allows Collagen to source animal-based biomaterials from Australia for their pericardium tissue for heart valve replacements, orthopedics, dental industry, wound healing, surgery, and other medical uses. Australia and New Zealand are often sought-after by companies looking for high quality animal-based biomaterials because they have strict controls and have been doing it for a long time. Collagen’s CEO, Jamal Rushdy, told Proactive Investors UK, “This recent patent further strengthens our position in sourcing tissue in Australia in a novel way. We believe the additional processing covered in this patent will be of significant interest to our existing customer base.”
Latest article
Fin-ished, for now: Aqua Cultured Foods shutters as funding dries up
In Chicago, a fermentation startup converting cellulose into seafood alternatives has wound down operations after failing to raise funds necessary to reach commercialization.
Established...
Mercedes unveils vegan-interior SUV at CES
In Nevada, Mercedes-Benz has showcased a new, vegan-interior GLC electronic SUV at the recent CES technology trade show in Las Vegas.
Vegan materials were...
Futerro files permits for French PLA site
In France, biobased chemicals maker Futerro has requested the relevant permits for its planned lactic acid and polylactic acid plant in France.
The plant, which...